Gyroscope Therapeutics Receives Up To $60M Equity Investment From Sanofi

Gyroscope Therapeutics, a London-based gene therapy company, has received an equity investment of up to $60 million from Sanofi. The investment will be used to fund ongoing clinical trials of GT005, a gene therapy for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Sanofi will initially invest $40 million, with an additional $20 million contingent on future events. As part of the agreement, a Sanofi R&D executive will join Gyroscope's Clinical Advisory Board, and Sanofi will have the right of first refusal on future transactions for GT005 in select geographies.

Sanofi Invests Up to $60 Million in Gyroscope Therapeutics for Gene Therapy Development

Gyroscope Therapeutics Holdings plc is a London, UK-based clinical-stage gene therapy company focused on diseases of the eye. It is developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness. Its GT005 is an AAV2-based gene therapy for GA secondary to AMD that is designed to be a one-time treatment delivered under the retina. It aims to restore balance to an overactive complement system, a part of the immune system, by increasing production of the Complement Factor I (CFI) protein, which regulates the activity of the complement system. Complement overactivation can lead to inflammation that damages healthy tissues, and it has been strongly correlated with the development and progression of AMD. GT005 is currently being evaluated in Phase II clinical trials for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a leading cause of blindness. GT005 has received Fast Track designation from the U.S. Food and Drug Administration for the treatment of people with GA. Gyroscope is headquartered in London with locations in Philadelphia and San Francisco.

A clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness.

4 years ago

Sanofi Invests Up to $60 Million in Gyroscope Therapeutics for Gene Therapy Development

ProblemHealthcare

Solution

Covered on